Becca Asquith

Professor Becca Asquith had a PhD in Theoretical Particle Physics at the University of Durham, and worked as a mathematical modeler for the UK government before shifting to Mathematical Immunology at Imperial. Her research focuses on the cytotoxic CD8+ T cell, as her group uses a novel combination of experimental, mathematical and bioinformatic techniques to investigate cell-mediated immunity, aiming to develop a predictive mathematical model of the human in vivo CD8+ T cell response in order to prevent and alleviate viral infection.

Lab Information

Imperial College London

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Bioinformatics 0 Immunology 0 Mathematical Modelling 0 CD8+ T cell Response 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Costa Del Amo P, Debebe B, Razavi-Mohseni M, et al. The Rules of Human T Cell Fate in vivo. Front Immunol. 2020;11:573. Published 2020 Apr 8. doi:10.3389/fimmu.2020.00573

  2. Debebe BJ, Boelen L, Lee JC, et al. Identifying the immune interactions underlying HLA class I disease associations. Elife. 2020;9:e54558. Published 2020 Apr 2. doi:10.7554/eLife.54558

  3. Macallan DC, Busch R, Asquith B. Current estimates of T cell kinetics in humans. Curr Opin Syst Biol. 2019;18:77-86. doi:10.1016/j.coisb.2019.10.002

  4. Boelen L, Debebe B, Silveira M, et al. Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol. 2018;3(29):eaao2892. doi:10.1126/sciimmunol.aao2892

  5. Costa Del Amo P, Lahoz-Beneytez J, Boelen L, et al. Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness. PLoS Biol. 2018;16(6):e2005523. Published 2018 Jun 22. doi:10.1371/journal.pbio.2005523


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2025 MolecularCloud